Irgd

1 study on Irgd curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.

Bottom line: TitrateLab currently curates 1 dated study on Irgd. The source summaries below describe published research; they do not establish product quality, safety, or clinical suitability.

Irgd studies and clinical research

2026-04-09 PubMed · preclinical animal · n preclinical

Engineered Exosomes with iRGD Peptide Target Pancreatic Cancer for RNAi Therapy

This study presents a highly promising and innovative strategy for targeted RNAi therapy against pancreatic cancer, leveraging the natural biocompatibility of exosomes and the specificity of the iRGD peptide. By effec…

Research tools

Free, no account — handy when you're working with Irgd.

Reconstitution calculator Bac water, concentration & insulin-unit math Verify a COA Look up a report number against our corpus

TitrateLab PRO

Unlock the complete evidence trail

Pro members save studies and unlock the full evidence breakdown and vendor lab data.

Complete vendor lab histories
Every linked certificate on file
Batch-level purity and quantity detail
Thousands of community reviews

Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.

$12 monthly or $33 lifetime

Create free account

TitrateLab

You must be 21 or older to enter.

TitrateLab provides research-use information on peptides for adults. Confirm your age to continue.

For research purposes only. Not for human consumption. By entering you agree to our Terms & Privacy.

Irgd studies and clinical research

Engineered Exosomes with iRGD Peptide Target Pancreatic Cancer for RNAi Therapy

Research tools